SecBot SecBot
8-K ·Filed Aug 20, 2026

URGN

UroGen Pharma Ltd.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago SEC0001437749-26-028590
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a small, early-stage pipeline expansion into head and neck cancer via a platform technology option. The $7M equity investment is modest relative to UroGen's $2.5B market cap. Monitor for future development milestones or exercise of the option, but the filing itself is not a near-term catalyst. No financial guidance or revenue impact was provided.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$46.80
T+0 close · Aug 20, 2026 · via day close
Latest settled
−44.06%
T+60 · $26.18
Vs SPY
−42.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $46.80entry
  2. T+1 · 3mo ago +0.13%α −0.28% · $46.86
  3. T+5 · 3mo ago −2.78%α −3.89% · $45.50
  4. T+20 · 2mo ago −7.59%α −7.59% · $43.25
  5. T+60 · 4d ago −44.06%α −42.98% · $26.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UroGen Pharma entered into an Option and Research License Agreement with IntraGel Therapeutics, securing an exclusive option for a worldwide license to develop and commercialize IntraGel's TumoCure product (using its SRGel sustained-release hydrogel platform) for advanced head and neck cancer, plus options for additional combination products. UroGen also agreed to invest up to $7,000,000 in IntraGel's equity. This is an early-stage, pre-clinical pipeline expansion into a new oncology indication with modest financial commitment, providing optionality without near-term revenue impact.

Key Facts

  • UroGen obtained an exclusive option for a worldwide license to develop and commercialize IntraGel's TumoCure product for advanced head and neck cancer.
  • UroGen also obtained options for exclusive worldwide licenses to develop additional products combining IntraGel's SRGel platform with compounds designated by UroGen.
  • UroGen agreed to invest up to $7,000,000 in IntraGel's equity securities.
  • The agreement was entered into on August 18, 2026.
  • The deal provides UroGen with a non-exclusive license to research and evaluate the SRGel platform.

Financial Impact

UroGen committed to invest up to $7,000,000 in IntraGel equity; no other financial terms disclosed.

cash

Risk Factors

  • The option may never be exercised; the TumoCure product is at an early stage and may fail in development.
  • The $7M equity investment in IntraGel is at risk if IntraGel's technology does not succeed.
  • No financial details on milestone payments, royalties, or license fees were disclosed, leaving deal economics unclear.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-028590
Document: 0001437749-26-028590-index-headers.html0001437749-26-028590
Document: 0001437749-26-028590-index.html0001437749-26-028590
Document: 0001437749-26-028590.txt0001437749-26-028590

Track record

16 reports on URGN

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Viewing Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026